Aethlon Medical Advances Hemopurifier® Trial and Enhances Operational Efficiency for Cancer Treatment

Aethlon Medical Advances in Hemopurifier® Cancer Trial Amid Operational Efficiency Gains

Aethlon Medical, Inc. (Nasdaq: AEMD) makes notable strides in its clinical development as it successfully completes the first treatment cohort of its Hemopurifier® trial for cancer. This trial, targeting patients with solid tumors who have not responded to anti-PD-1 immunotherapy, demonstrates that all participants tolerated the four-hour Hemopurifier treatment without experiencing serious adverse events or dose-limiting toxicities. The completion of this cohort signifies a crucial step forward in Aethlon's efforts to expand treatment options for difficult-to-treat cancer cases, potentially positioning the Hemopurifier as a valuable therapeutic tool in oncology.

In a significant development, Aethlon amends the trial protocol to broaden patient eligibility, allowing individuals under various treatment regimens—including those receiving anti-PD-1 agents like pembrolizumab (Keytruda®) and nivolumab (Opdivo®)—to participate. This strategic adjustment reflects Aethlon's commitment to maximizing patient inclusion and relevance to current treatment practices. The ongoing trial also reports promising preclinical data, showcasing a remarkable 98.5% removal rate of platelet-derived extracellular vesicles during simulated Hemopurifier treatments, reinforcing the device's potential efficacy.

Financially, Aethlon is enhancing its operational efficiency, reporting a 31.6% reduction in operating expenses. This improvement not only strengthens the company's financial position but also enables further investment in crucial clinical research. The independent Data Safety Monitoring Board (DSMB) has already reviewed the safety data from the first cohort and recommended progressing to a second cohort, which will involve participants receiving two Hemopurifier treatments within one week. With all three clinical sites in Australia actively screening for this next cohort under the amended protocol, Aethlon is poised to align its trials more closely with current medical standards, thereby increasing the likelihood of successful outcomes.

In addition to its cancer initiatives, Aethlon continues its collaboration with UCSF on research related to Long COVID, with recent findings presented at the Keystone Symposium. This work underscores the company’s commitment to addressing significant health challenges beyond oncology. Aethlon's strategic advancements in clinical trials and operational efficiency highlight its potential to significantly impact the therapeutic landscape for both cancer and infectious diseases. A conference call is scheduled for today at 4:30 p.m. ET, providing further insights into these developments and the company’s future directions.